CLVS Key Statistics, Chart & Performance
The current stock price of CLVS is 0.0812 USD. In the past month the price decreased by -76.84%. In the past year, price decreased by -97.44%.
CLVS Technical Analysis
CLVS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CLVS. Both the profitability and financial health of CLVS have multiple concerns.
CLVS Financial Highlights
Over the last trailing twelve months CLVS reported a non-GAAP Earnings per Share(EPS) of -1.81. The EPS increased by 36.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLVS Forecast & Estimates
7 analysts have analysed CLVS and the average price target is 2.04 USD. This implies a price increase of 2412.32% is expected in the next year compared to the current price of 0.0812.
For the next year, analysts expect an EPS growth of 28.29% and a revenue growth -14% for CLVS
CLVS Ownership
CLVS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.18 | 393.136B | ||
| AMGN | AMGEN INC | 16.2 | 196.357B | ||
| GILD | GILEAD SCIENCES INC | 17.43 | 182.665B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.54 | 117.594B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.77 | 79.341B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.4 | 42.669B | ||
| INSM | INSMED INC | N/A | 31.681B | ||
| NTRA | NATERA INC | N/A | 29.21B | ||
| BIIB | BIOGEN INC | 12.56 | 27.736B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.13 | 20.376B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLVS
Company Profile
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. The company is headquartered in Boulder, Colorado and currently employs 413 full-time employees. The company went IPO on 2011-11-16. The firm is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286, is an investigational diagnostic and therapeutic agent targeting fibroblast activation protein (FAP). The company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).
Company Info
CLOVIS ONCOLOGY INC
Suite 100, 2525 28Th Street
Boulder COLORADO 80301 US
CEO: Patrick J. Mahaffy
Employees: 413
Phone: 13036255000.0
CLOVIS ONCOLOGY INC / CLVS FAQ
Can you describe the business of CLOVIS ONCOLOGY INC?
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. The company is headquartered in Boulder, Colorado and currently employs 413 full-time employees. The company went IPO on 2011-11-16. The firm is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286, is an investigational diagnostic and therapeutic agent targeting fibroblast activation protein (FAP). The company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).
What is the stock price of CLOVIS ONCOLOGY INC today?
The current stock price of CLVS is 0.0812 USD. The price decreased by -5.58% in the last trading session.
Does CLOVIS ONCOLOGY INC pay dividends?
CLVS does not pay a dividend.
What is the ChartMill rating of CLOVIS ONCOLOGY INC stock?
CLVS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists CLVS stock?
CLVS stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for CLOVIS ONCOLOGY INC?
CLOVIS ONCOLOGY INC (CLVS) operates in the Health Care sector and the Biotechnology industry.
When does CLOVIS ONCOLOGY INC (CLVS) report earnings?
CLOVIS ONCOLOGY INC (CLVS) will report earnings on 2023-02-21.